Shots:

• The first patient has been dosed in a P-II/III clinical trial of HLX10 in combination with HLX04 (bevacizumab) and CT for 1L treatment of mCRC
• The combination regimen aims to benefit patients with I-O mAbs combination therapy as early as possible- further delaying the disease progression and improving the survival status of patients with mCRC
• HLX10 is a recombinant humanized anti- PD-1 mAb injection. HLX10 in combination with HLX04 is the first domestic mAbs combination therapy approved for clinical trials in China- which has been carried out late-stage clinical studies in NSCLC and HCC previously

  Ref: Henlius | Image: Henlius